Open AccessTumor antigen delivered by Salmonella III secretion protein fused with heat shock protein 70 induces protection and eradication against murine melanoma
Author(s) -
Zhu Xiangying,
Zhou Ping,
Cai Jianguo,
Yang Guimei,
Liang Shenghua,
Ren Daming
Publication year - 2010
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/j.1349-7006.2010.01722.x
Subject(s) - ctl* , immune system , antigen , cytotoxic t cell , cancer vaccine , immunology , tumor antigen , cancer immunotherapy , acquired immune system , biology , salmonella , secretion , heat shock protein , cancer research , melanoma , immunotherapy , cd8 , in vitro , bacteria , biochemistry , genetics , gene
Attenuated Salmonella typhimurium possess the ability to stimulate innate immune responses and preferentially allocate within the solid tumor. These two main characteristics make attenuated Salmonella one of the most attractive vehicles for development of vaccine and also targeted cancer therapies. However, location of Salmonella prevents the process of antigen presentation. Salmonella Type III secretion system can be utilized to circumvent this problem because this system secretes the protein it encoded outside the cells. Heat shock protein 70 (Hsp70) is referred to as an “immunochaperone” for its capacity to elicit tumor‐specific adaptive immune responses in the form of Hsp70‐TAA (tumor associated antigen) complex. Hsp70 facilitates the cross‐presentation of exogenous antigens through its receptor on antigen‐presenting cells and therefore activates an antigen‐specific cytotoxic T lymphocyte (CTL) response, which can directly contribute to potent anti‐tumor immunity. Here, we designed a novel therapeutic vaccine utilizing the type III secretion system and Hsp70 to deliver and present the tumor‐specific antigen. This live recombinant bacteria vaccine, when administrated orally, successfully broke the immune tolerance, induced a specific CTL response against tumor cells, and therefore revealed protective and therapeutic effects against generation and growth of B16F10 melanoma in C57BL/6J mice. ( Cancer Sci 2010; 101: 2621–2628)